PUBLISHER: The Business Research Company | PRODUCT CODE: 1763100
PUBLISHER: The Business Research Company | PRODUCT CODE: 1763100
Thyrogen (thyrotropin alfa) is a synthetic version of thyroid-stimulating hormone, utilized to detect thyroid cancer remnants in patients who have undergone thyroidectomy. It encourages the thyroid gland to absorb radioactive iodine, enabling diagnostic imaging and treatment, all without requiring thyroid hormone withdrawal.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
Primary forms of thyrogen are vail and pre-filled. Vail Thyrogen refers to the distribution or usage of thyrotropin alfa by Genzyme in a specific setting, like a medical facility or practice in Vail. It includes product types such as thyrogen powder and injection, which are employed for diagnostic and therapeutic purposes. The end users of these products include hospitals, diagnostic centers, specialty clinics, and other healthcare providers.
The thyrogen market research report is one of a series of new reports from The Business Research Company that provides thyrogen market statistics, including thyrogen industry global market size, regional shares, competitors with a thyrogen market share, detailed thyrogen market segments, market trends and opportunities, and any further data you may need to thrive in the thyrogen industry. This thyrogen market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The thyrogen market size is expected to see strong growth in the next few years. It will grow to $1,610 million in 2029 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to increasing incidence of thyroid cancer, increasing focus on patient-centered healthcare, rising awareness and diagnosis of thyroid problems, increasing incidence of anaplastic thyroid cancer, and increasing awareness and education. Major trends in the forecast period include advancement in diagnostic technologies, technological innovations in treatment, product launches, innovative oncology drugs, and biotechnology advancements.
The increasing incidence of thyroid cancer is expected to drive the growth of the thyrogen market. Thyroid cancer originates in the thyroid gland and often presents as a lump or nodule in the neck. The rise in thyroid cancer cases is largely due to better detection through advanced imaging and biopsy techniques, as well as factors like radiation exposure and environmental changes. Thyrogen is used in thyroid cancer treatment to stimulate the thyroid gland, which aids in the detection of residual cancer and enhances the effectiveness of radioactive iodine therapy. For example, in January 2024, the American Cancer Society projected approximately 44,020 new cases of thyroid cancer in the U.S., up from 43,720 in 2023, including 12,500 in men and 31,520 in women. The anticipated increase in thyroid cancer cases is driving the growth of the thyrogen market.
The rising focus on personalized medicine is expected to significantly propel the growth of the thyrogen market. Personalized medicine tailors healthcare treatments based on individual genetic, lifestyle, and environmental factors, which leads to more precise healthcare outcomes, improved patient care, and reduced adverse effects. Thyrogen is increasingly being utilized in precision medicine, particularly for differentiated thyroid cancer, where it provides targeted diagnostic and therapeutic interventions, especially in patients with radioiodine-refractory disease. Thyrogen works by engaging thyroid-stimulating hormone receptors, offering a personalized treatment approach. For example, in February 2024, a report by the Personalized Medicine Coalition highlighted that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. The newly approved treatments included seven cancer drugs, reflecting the growing application of personalized medicine in oncology. The increasing focus on personalized treatments, including the use of Thyrogen for targeted interventions in thyroid cancer, is driving the growth of the thyrogen market.
A key trend in the thyrogen market focuses on innovative applications, such as its use as a theranostic tool for diagnosing and treating differentiated thyroid cancer. This dual-purpose tool combines both diagnostic imaging and therapeutic applications, particularly for patients with radioiodine-refractory disease, by targeting thyroid-stimulating hormone receptors. For example, in June 2024, the Society of Nuclear Medicine and Molecular Imaging published research in the Journal of Nuclear Medicine, exploring the use of Thyrogen as a radiopharmaceutical for diagnosing and treating radioiodine-refractory differentiated thyroid cancer (DTC). This innovation reflects the shift towards precision medicine, where treatments and diagnostic methods are tailored to specific patient needs. Ongoing investment in research and innovation also supports the use of recombinant TSH in emerging clinical scenarios, further driving its adoption in the treatment of thyroid cancer.
Major players operating in the thyrogen market are Sanofi S.A.
North America was the largest region in the thyrogen market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in thyrogen report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the thyrogen market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The thyrogen market consists of sales of products including, levothyroxine, radioactive iodine (I-131), proleukin, and Lugol's iodine solution. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Thyrogen Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on thyrogen market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for thyrogen ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The thyrogen market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.